Molecular Partners AG (MOLN)

4.0700 +0.4100 (+11.20%) 市場開市。 截至 11:31AM EDT。

Molecular Partners AG

Wagistrasse 14
Schlieren 8952
Switzerland
41 44 755 77 00
https://www.molecularpartners.com

版塊: Healthcare
行業: Biotechnology
全職員工: 167

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Patrick Amstutz Ph.D.	Co-Founder, CEO, Member of Management Board & Director	729.01k	無	1975
Dr. Michael Tobias Stumpp Ph.D.	Co-Founder, Executive VP of Projects & Member of Management Board	無	無	1972
Mr. Robert Hendriks	Senior VP of Finance	無	無	無
Mr. Alexander Zurcher	COO & Member of Management Board	無	無	1975
Ms. Renate Gloggner	Executive VP of People & Community and Member of Management Board	無	無	1970
Mr. Daniel Steiner Ph.D.	Senior Vice President of Research & Technology	無	無	無
Mr. Seth D. Lewis	Senior Vice President of Investor Relations, Communications & Strategy	無	無	無
Mr. Michael Pitzner	General Counsel, Compliance Officer, Senior VP Legal & Business Development	無	無	無
Dr. Pamela A. Trail Ph.D.	Strategic Consultant	無	無	1956
Ms. Anne Goubier D.V.M., Ph.D.	Senior Vice President of Research & Early Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

公司管治

截至 無 止，Molecular Partners AG 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。